February 22, 2023


U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549



Jason Drory



VectivBio Holding AG

Registration Statement on Form F-3

Filed January 27, 2023

File No. 333-269450

Acceleration Request

Requested Date: February 24, 2023

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-269450) (the “Registration Statement”), to become effective on February 24, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff. The Registrant hereby authorizes Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brandon Fenn of Cooley LLP at (212) 479-6626.

[Signature page follows]

Very truly yours,
VectivBio Holding AG
By:    /s/ Luca Santarelli
Luca Santarelli
Chief Executive Officer



Scott Applebaum, VectivBio Holding AG

Brandon Fenn, Cooley LLP

Dayne Brown, Cooley LLP

Andreas Müller, Homburger AG